Pfizer Stock (PFE) Before the Bell on November 14, 2025: Metsera Deal Closes, BioNTech Stake Cut and Guidance Raised
As Wall Street heads into Friday’s session, Pfizer stock is trading slightly lower in premarket action while investors digest a trio of big developments: the completed acquisition of obesity‑drug developer Metsera, a sharp reduction in Pfizer’s stake in BioNTech, and a recent earnings report that lifted 2025 profit guidance but confirmed that COVID revenue continues to fade.Pfizer+2BioSpace+2 Benzinga’s real‑time quote shows Pfizer (NYSE: PFE) around $25.6 ahead of the U.S. market open, roughly 1% belowThursday’s close of $25.79, putting the shares on track for a mildly negative start to the day.Benzinga+1 Below is what traders and long‑term investors should know before the opening bell.